Enzalutamide treatment and risk for seizures
The “Warnings and Precautions” section of the product prescribing information for enzalutamide (Xtandi) includes the following statement: Seizure occurred in 0.5% of patients receiving XTANDI. In...
View ArticleImproving survival among men with oligorecurrent prostate cancer?
A newly published article in the Journal of Clinical Oncology reports data from a small, randomized, multicenter, Phase II clinical trial comparing active monitoring to treatment of men with recurrent,...
View ArticleWhat to do first for men with mCRPC
The currently “great unanswered” question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic...
View ArticleA PSMA-based PET scan can change SRT decisions
The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy. Formerly, the only tools we had were scans that could only detect very...
View ArticleMajor US insurer to cover use of HIFU for treatment of radiorecurrent...
According to a media release issued on March 18 by EDAP TMS, the US healthcare insurance firm CIGNA has agreed to cover the use of high-intensity focal ultrasound (HIFU) as a second-line, salvage...
View ArticleShould perineural invasion influence active surveillance and radiation...
Perineural invasion (PNI) is a risk factor detected on a biopsy in 15 to 38 percent of men with a prostate cancer diagnosis. The presence of PNI means that the pathologist saw nerves infiltrated with...
View ArticleASCO issues new guidelines on treatment of metastatic prostate cancer
New guidelines on the management of metastatic, hormone-sensitive prostate cancer have just been released by the American Society for Clinical Oncology (ASCO), based primarily on data from the...
View ArticleTwo leading women talk about the future of treatment of advanced prostate cancer
Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single...
View ArticleTestosterone supplements and new AUA guidelines on management of testosterone...
The increasingly widespread use of testosterone supplements has been of concern for many years. In particular, for men with a history of prostate cancer diagnosis, the appropriate use of testosterone...
View ArticleWhat’s the “best” form of first-line treatment for mHSPC today?
A new paper in the Annals of Oncology has addressed the critical question regarding what might be “the best” way we currently have to start treatment for a man newly diagnosed with metastatic,...
View ArticleOn statins: a race-related update
It is relatively common knowledge — although never actually proven in a large, randomized, placebo-controlled trial — that statins like rosuvastatin (Crestor) and atorvastatin (Lipitor) may be helpful...
View ArticleA prostate cancer book that is uniquely useful
There is a large number of books for patients that deal with a diagnosis and management of prostate cancer. However, there is a relatively small number of books that are really valuable for a large...
View Article“The best” therapy for Gleason 10 prostate cancer
We recently saw (see this link) that men diagnosed with a Gleason score (GS) of 9 or 10 had lower rates of metastasis and better prostate-cancer survival if they were treated with a combination of...
View ArticleFDA approves use of enzalutamide (Xtandi) for nmCRPC
As we predicted just a couple of weeks ago, on Friday the US Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant...
View ArticleSpeed of change in the management of prostate cancer
One of our regular correspondents (who lives in England) was recently told something rather interesting by the Consultant Urologist he sees in the UK. The gist of the Consultant Urologist’s comment was...
View ArticleEarly data from the PROPS imaging trial prior to SRT
A recent presentation by Pouliot Frederick, MD, at the annual meeting of the Canadian Urological Association in Halifax, Nova Scotia, provided information on the roles of multiparametric MRI,...
View ArticleProstate cancer outcomes today vs. outcomes yesteryear
As some of us have long suspected and understood, using data from men treated 20+ years ago as a guide to what would happen if you were treated the same way today is not really a very good idea. A...
View ArticleThe “war” on cancer: are we “winning” or “losing” or what?
Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the...
View ArticleCan RP + EBRT + ADT provide equal outcomes to brachy boost therapy + ADT in...
As we have seen previously (see this link), among men with Gleason 9 or 10 disease, brachy boost therapy (BBT) provided better oncological outcomes compared to either radical prostatectomy (RP) alone...
View ArticleWhat patients think and understand can impact their decisions and their outcomes
It has long been appreciated that African-American males have higher risk for diagnosis with prostate cancer, and higher risk for prostate cancer-specific mortality, than those of other ethnic origins...
View Article